Akyildiz, A. Et Al. 2023. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey. MEDICINE , vol.102, no.45 , 1-8.

Akyildiz, A., Guven, D. C., Ozluk, A. A., Ismayilov, R., Mutlu, E., Unal, O. U., ... Yildiz, I.(2023). The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey. MEDICINE , vol.102, no.45, 1-8.

Akyildiz, Arif Et Al. "The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey," MEDICINE , vol.102, no.45, 1-8, 2023

Akyildiz, Arif Et Al. "The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey." MEDICINE , vol.102, no.45, pp.1-8, 2023

Akyildiz, A. Et Al. (2023) . "The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey." MEDICINE , vol.102, no.45, pp.1-8.

@article{article, author={Arif Akyildiz Et Al. }, title={The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey}, journal={MEDICINE}, year=2023, pages={1-8} }